Oramed Pharmaceuticals
ORMP
26 hedge funds and large institutions have $2.94M invested in Oramed Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
2,900% more call options, than puts
Call options by funds: $30K | Put options by funds: $1K
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
4% more funds holding
Funds holding: 25 → 26 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
1.35% less ownership
Funds ownership: 6.18% → 4.83% (-1.3%)
23% less capital invested
Capital invested by funds: $3.83M → $2.94M (-$894K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$187K |
| 2 |
Jane Street
New York
|
+$153K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$59.8K |
| 4 |
BlackRock
New York
|
+$8.55K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$6.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.15M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$38K |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$35.3K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$18.5K |
| 5 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GT
26
Glenmede Trust
Philadelphia,
Pennsylvania
| $71 | – | – | – |
|
|
27
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| – | -$38K | -10,527 | Closed |
|
|
SWM
28
SeaCrest Wealth Management
Purchase,
New York
| – | -$5K | -1,500 | Closed |
|
29
Nordea Investment Management
Stockholm,
Sweden
| – | -$2K | -500 | Closed |
|
ORMP Hedge Fund Activity: Q2 2019 in Review
26 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2019, worth a combined $2.94M — down 23% from $3.83M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ORMP positions and 3 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $187K. The largest seller was Sabby Management, cutting an estimated $1.15M.
- 26 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2019, up from 25 in Q1 2019.
- Funds reported $2.94M of Oramed Pharmaceuticals stock for Q2 2019, down 23% quarter-over-quarter.
- 4 funds opened new Oramed Pharmaceuticals positions in Q2 2019 and 3 closed out, a net change of +1 holder.
- The largest Oramed Pharmaceuticals buyer in Q2 2019 was Renaissance Technologies, an estimated $187K added.
- The largest Oramed Pharmaceuticals seller in Q2 2019 was Sabby Management, an estimated $1.15M sold.
Based on aggregated 13F filings for Q2 2019.